Raksharab Injection 1 ml Vial

babies: it is not applicable for babies. lactating mother: it is safe.
studies have shown that the drug does not represent any significant risk to the baby. pregnancy: it is safe in pregnancy.
animal studies have shown that it has low or no adverse effects on the baby. however, there are limited human studies.
driving: it is unknown whether the raksharab vaccine alters the ability to drive. do not drive if you experience any symptoms that affect your ability to concentrate and react. alcohol: it is unknown whether it is safe to consume alcohol with the raksharab vaccine.
seek doctor advice before using this medication. liver: limited information available on the use of raksharab vaccine in patients with kidney disease.
seek doctor advice before using this medication. kidney: limited information available on the use of raksharab vaccine in patients with kidney disease. seek doctor advice before using this medication..

pain joint pain injection site redness injection site swelling swelling of lymph nodes.

raksharab injection is an inactivated vaccine. it works by developing immunity by forming antibodies which are proteins that protect against infection caused by viruses..

consult your doctor immediately if you missed the dose of raksharab injection..

• raksharab vaccine helps in preventing rabies • healthcare professionals will administer raksharab injection under medical supervision • the vaccine is given as a course of three injections on days 0, 7, and 28. a booster dose is needed one year after completing this course • if you are immunized against rabies and bitten by an animal suspected of having rabies, two doses of the vaccine are needed, first on the day of the bite and second on day three after the bite • do not take the raksharab vaccine if you have a weak immune system • do not stop the medication suddenly without informing your doctor.

• raksharab + adalimumab: concurrent use leads to a decrease in the therapeutic efficacy of raksharab inactivated antigen • raksharab + alefacept: concurrent use leads to a decrease in the therapeutic efficacy of raksharab inactivated antigen • raksharab + anakinra: concurrent use leads to a decrease in the therapeutic efficacy of raksharab inactivated antigen • raksharab + altretamine: concurrent use leads to a decrease in the therapeutic efficacy of raksharab inactivated antigen • raksharab + budesonide: concurrent use leads to a decrease in the therapeutic efficacy of raksharab inactivated antigen.